Bronchodilator reversibility testing in COPD: which parameter?

N. Bautin, C. Chenivesse, T. Perez, R. Matran (Lille, France)

Source: Annual Congress 2006 - Spirometric assessment of lung pathophysiology
Session: Spirometric assessment of lung pathophysiology
Session type: Thematic Poster Session
Number: 1212
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Bautin, C. Chenivesse, T. Perez, R. Matran (Lille, France). Bronchodilator reversibility testing in COPD: which parameter?. Eur Respir J 2006; 28: Suppl. 50, 1212

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bronchodilator reversibility - differences between asthma and COPD
Source: International Congress 2019 – Respiratory function assessment in disease
Year: 2019


Ventilation heterogeneity reversibility: asthma, COPD or ACOS?
Source: International Congress 2017 – Novel imaging findings characterising various lung diseases and their prognoses
Year: 2017



Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016

Bronchodilator reversibility (BDR) - should we measure it in adults with symptoms but without obstructed spirometry?
Source: Virtual Congress 2021 – Primary care diagnosis and multimorbidities
Year: 2021


Body-plethysmographic measurements of bronchodilator response in stable COPD
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014


Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Bronchodilator responsiveness in patients with COPD
Source: Eur Respir J 2008; 31: 742-750
Year: 2008



Bronchodilator reversibility in asthma and COPD: findings from three large population studies
Source: Eur Respir J, 54 (3) 1900561; 10.1183/13993003.00561-2019
Year: 2019



Bronchodilation test estimation using spirometry and electrical impedance analysis in bronchial asthma and COPD patients
Source: International Congress 2015 – Lung function: new findings and approaches
Year: 2015


Spirometry parameters and adherence to COPD treatment:  is there association?
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Usefulness of post bronchodilator FVC in the evaluation and spirometric evolution of COPD patients
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013


Reversibility at pulmonary function tests: can it have implications in patients with COPD?
Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD
Year: 2021


Bronchodilator response of advanced lung function parameters depending on COPD severity
Source: International Congress 2016 – Functional assessment of the airways
Year: 2016

Are bronchodilator drugs really useful in COPD?
Source: Eur Respir J 2001; 18: Suppl. 33, 94s
Year: 2001

Airway calibre variability by forced oscillation technique: a sensitive indicator of bronchodilator effect in asthmatic children
Source: Annual Congress 2005 - Monitoring paediatric asthma
Year: 2005


Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019

Does positive bronchodilator reversibility testing predict positive bronchoprovocative methacholine challenge testing in suspected asthma patients
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016


Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013


Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020


REVERDIL study: validity of salbutamol in determining COPD reversibility prior to formoterol treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 50s
Year: 2003